Fibrocell Science Inc (NASDAQ:FCSC) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 1,083,658 shares, an increase of 43.3% from the October 31st total of 756,335 shares. Approximately 11.9% of the shares of the stock are short sold. Based on an average trading volume of 116,142 shares, the days-to-cover ratio is currently 9.3 days.
Several research analysts recently weighed in on the stock. HC Wainwright set a $6.00 price target on shares of Fibrocell Science and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research downgraded shares of Fibrocell Science from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. ValuEngine downgraded shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. Finally, Canaccord Genuity restated a “buy” rating and set a $7.00 price target (up previously from $3.00) on shares of Fibrocell Science in a research report on Monday, September 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $5.21.
Fibrocell Science (NASDAQ FCSC) opened at $1.37 on Friday. Fibrocell Science has a 1 year low of $1.32 and a 1 year high of $4.64.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pura Vida Investments LLC acquired a new position in shares of Fibrocell Science during the 3rd quarter worth about $909,000. Parametric Portfolio Associates LLC raised its position in shares of Fibrocell Science by 264.0% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock worth $194,000 after purchasing an additional 35,000 shares during the last quarter. Finally, Creative Planning raised its position in shares of Fibrocell Science by 395.3% during the 2nd quarter. Creative Planning now owns 61,090 shares of the company’s stock worth $245,000 after purchasing an additional 48,755 shares during the last quarter. Hedge funds and other institutional investors own 55.81% of the company’s stock.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.